1. American Psychiatric Association. Benzodiazepine dependence, toxicity, and abuse. A Task Force Report of the American Psychiatric Association, 1990.

2. Angst J, Vollrath M, Merikangas KR, Ernst C. Comorbidity of anxiety and depression in the Zurich cohort study of young adults. In: Maser and Cloninger, eds. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990; 123–137.

3. Ashton H. Benzodiazepine withdrawal: an unfinished story. Br Med J 1984;288:1135–1140.

4. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413–422.

5. Barlow DH, Blanchard EB, Vermilyea JA, Vermilyea BB, DiNardo PA. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry 1986;143:40–44.

6. Barlow DH, Cohen AS, Waddell MT, Vermilyea BB, Klosko JS, Blanchard EB, Di Nardo PA. Panic and generalized anxiety disorders: nature and treatment. Behav Ther 1984;15:431–449.

7. Beitman BD, Mukerji V, Lamberti JW, Schmid L, De Rosear L, Kushner M, Flaker G, Basha I. Panic disorder in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1989;63:1399–1403.

8. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44–50.

9. Borkovec TD, Mathews AM. Treatment of nonphobic anxiety disorders: a comparison of nondirective, cognitive, and coping desensitization therapy. J Consult Clin Psychol 1988;56:877–884.

10. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992;60:835–844.

11. Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988;145:1501–1506.

12. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160: 191–202.

13. Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. J Clin Psychiatry 1991;52 (Suppl):16–20.

14. de Wit H, McCracken SM, Uhlenhuth EH, Johanson CE. Diazepam preference in subjects seeking treatment for anxiety. NIDA Res Monogr 1987;76:248–254.

15. Dilsaver SC. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Acta Psychiatr Scand 1989;79:113–117.

16. Durham RC, Turvey AA. Cognitive therapy vs behavior therapy in the treatment of chronic general anxiety. Behav Res Ther 1987;25:229–234.

17. Fontaine R, Chouinard G, Annable A. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984;141:848–852.

18. Friedman CJ, Shear MK, Frances AJ. DSM-III personality disorders in panic patients. J Personal Dis 1987;1:132–135.

19. Gelernter CS, Stein MB, Tancer ME, Uhde TW. An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. J Clin Psychiatry 1992;53:23–27.

20. Katon W, Von Korff M, Lin E, Lipscomb P, Russo J, Wagner E, Polk E. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355–362.

21. Kendall PC, Kortlander E, Chansky TE, Brady EU. Comorbidity of anxiety and depression in youth: treatment implications. J Consult Clin Psychol 1992;60:869–880.

22. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry 1992;49:716–722.

23. Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent psychopathology. I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993;102:133–144.

24. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290–300.

25. Lucki I, Rickels K. The effect of anxiolytic drugs on memory in anxious subjects. In: Hindmarch I, Ott H, eds. Benzodiazepine receptor ligands, memory and information processing. Berlin: Springer-Verlag, 1988;128–139.

26. Lucki I, Volpicelli JR, Schweizer E. Differential craving between recovering abstinent alcoholic-dependent subjects and therapeutic users of benzodiazepines. NIDA Res Monogr 1991;105:322–323.

27. Lydiard RB, Fossey MD, Ballenger JC. Irritable bowel syndrome in patients with panic disorder [Letter]. Am J Psychiatry 1991;148:1614.

28. Markovitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psychiatry 1989;46:984–992.

29. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993;150:600–607.

30. Mavissakalian M, Michelson I. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986;143:1106–1112.

31. McCracken SG, de Wit H, Uhlenhuth EH, Johanson CE. Preference for diazepam in anxious adults. J Clin Psychopharmacol 1990;10:190–196.

32. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984;251:375–379.

33. Miller LG, Woolverton S, Greenblatt DJ, Lopez F, Roy RB, Shader RI. Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. Biochem Pharmacol 1989;38:3773–3777.

34. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study. Arch Gen Psychiatry 1989;46:993–999.

35. Noyes R, Clancy J, Hoenk PR, Slymen DJ. The prognosis of anxiety disorders. Arch Gen Psychiatry 1980;37:173–178.

36. Noyes R, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affective Disord 1989;16:249–256.

37. Noyes R Jr, Woodman C, Garvey MJ, Cook BL, Suelzer M, Anderson DJ. Generalized anxiety disorder versus panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 1992;180:369–379.

38. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry 1988;45:429–436.

39. Pollack MH, Otto MW, Rosenbaum JF, Sachs GS. Personality disorders in patients with panic disorder: association with childhood anxiety disorders, early trauma, comorbidity, and chronicity. Compr Psychiatry 1992;33:78–83.

40. Power KG, Simpson RJ, Swanson V, Wallace LA, Feistner ATC, Sharp D. A controlled comparison of cognitive-behavior therapy, diazepam, and placebo, alone and in combination, for the treatment of generalized anxiety disorder. J Anx Disorders 1990;4:267–292.

41. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990;83:194–198.

42. Rickels K, Case WG, Diamond L. Relapse after short-term drug therapy in neurotic outpatients. Int Pharmacopsychiatry 1980;15: 186–192.

43. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA 1983;250:767–771.

44. Rickels K, Case WG, Downing RW, Fridman R. One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol 1986;6:32–36.

45. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebocontrolled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993;50:884–895.

46. Rickels K, Fox IL, Greenblatt DJ. Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 1988;145:312–317.

47. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444–450.

48. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990;10:101S–110S.

49. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899–907.

50. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61–68.

51. Robins L, Regier DA, eds. Psychiatric disorder in America. New York: Free Press, 1991.

52. Roy-Byrne PP, Cowley DL, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:534–538.

53. Sanderson WC, Wetzler S. Chronic anxiety and generalized anxiety disorder: issues in comorbidity. In: Rapee RM, Barlow DH, eds. Chronic anxiety, generalized anxiety disorder, and mixed anxiety depression. New York: Guilford Press, 1991;119–135.

54. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282–288.

55. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251–256.

56. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993;150:1210–1215.

57. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990;47:908–915.

58. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51–60.

59. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51–59.

60. Smail P, Stockwell T, Canter S, Hodgson R. Alcohol dependence and phobic anxiety states. I. A prevalence study. Br J Psychiatry 1984;144:53–57.

61. Starcevic V, Uhlenhuth EH, Kellner R, Pathak D. Patterns of comorbidity in panic disorder and agoraphobia. Psychiatry Res 1992;42:171–183.

62. Starcevic V, Uhlenhuth EH, Kellner R, Pathak D. Comparison of primary and secondary panic disorder: a preliminary report. J Affective Disord 1993;27:81–86.

63. Thyer BA, Parrish RT, Himle J, Cameron OG, Curtis GC, Nesse RM. Alcohol abuse among clinically anxious patients. Behavior Res Ther 1986;24:357–359.

64. Tyrer P. The benzodiazepine post-withdrawal syndrome [Guest editorial]. Stress Med 1991;7:1–2.

65. Tyrer P, Seivewright N, Ferguson B, Tyrer J. The general neurotic syndrome: a coaxial diagnosis of anxiety, depression and personality disorder. Acta Psychiatr Scand 1992;85:201–206.

66. Uhlenhuth EH, Balter MB, Mellinger GD, Cisin IH, Clinthorne J. Symptom checklist syndromes in the general population: correlations with psychotherapeutic drug use. Arch Gen Psychiatry 1983;40:1167–1173.

67. Uhlenhuth EH, Balter MB, Mellinger GD, Cisin IH, Clinthorne J. Anxiety disorders: prevalence and treatment. Curr Med Res Opin 1984;8(Suppl 4):37–47.

68. Van Ameringen M, Mancini C, Styan G, Donison D. Relationship of social phobia with other psychiatric illness. J Affective Disord 1991;21:93–99.

69. Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279–283.

70. Whitaker A, Johnson J, Shaffer D, Rapoport JL, Kalikow K, Walsh T, Davies M, Braiman S, Dolinsky A. Uncommon troubles in young people: prevalence estimates of selected psychiatric disorders in a nonreferred adolescent population. Arch Gen Psychiatry 1990; 47:487–496.

71. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992;44:155–186.